Sandbox Reserved 1493: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 131: | Line 131: | ||
=== Inhibitors === | === Inhibitors === | ||
αIIbβ3 is a target of '''blocker drugs''' such as | αIIbβ3 is a target of '''blocker drugs''' such as abciximab (chimeric Fab fragment), <scene name='80/802667/2vdn_epti/1'>eptifibatide</scene> (synthetic peptide inhibitor) and tirofiban (synthetic non-peptide inhibitor). Such antagonists inhibit the binding of ligands to αIIbβ3 and thus platelet aggregation. | ||
These drugs are currently prescribed to patients with acute coronary syndromes (ACS), Cardiovascular diseases (CVD) such as myocardial infarction, or to patients who undergo PCI or other thrombotic diseases. | These drugs are currently prescribed to patients with acute coronary syndromes (ACS), Cardiovascular diseases (CVD) such as myocardial infarction, or to patients who undergo PCI or other thrombotic diseases. | ||
| Line 138: | Line 138: | ||
== References == | == References == | ||
Displays of fibrinogen and | ''Displays of fibrinogen and eptifibatide ligands are made thanks to 2VDO and 2VDN.'' | ||
Structure and function: | Structure and function: | ||
